vs
Side-by-side financial comparison of IHS Holding Ltd (IHS) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $254.0M, roughly 1.2× IHS Holding Ltd). On growth, IHS Holding Ltd posted the faster year-over-year revenue change (0.1% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -22.0%).
IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world, with operations across Africa and Latin America. It is the fifth-largest independent multinational tower company in the world.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
IHS vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $254.0M | $295.9M |
| Net Profit | — | $38.0M |
| Gross Margin | 83.6% | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | — | 12.8% |
| Revenue YoY | 0.1% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $254.0M | $295.9M | ||
| Q3 25 | $455.1M | — | ||
| Q2 25 | $433.3M | $317.0M | ||
| Q1 25 | $439.6M | $316.2M | ||
| Q4 24 | $253.8M | $297.0M | ||
| Q3 24 | $420.3M | $289.5M | ||
| Q2 24 | $435.4M | $306.1M | ||
| Q1 24 | $417.7M | $303.4M |
| Q4 25 | — | $38.0M | ||
| Q3 25 | $147.4M | — | ||
| Q2 25 | $32.3M | $-17.7M | ||
| Q1 25 | $30.7M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $-205.7M | $33.6M | ||
| Q2 24 | $-124.3M | $40.6M | ||
| Q1 24 | $-1.6B | $49.1M |
| Q4 25 | 83.6% | 64.6% | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 51.3% | 62.7% | ||
| Q1 25 | 51.4% | 67.9% | ||
| Q4 24 | 72.1% | 65.3% | ||
| Q3 24 | 52.0% | 63.2% | ||
| Q2 24 | 52.5% | 66.4% | ||
| Q1 24 | 39.1% | 67.4% |
| Q4 25 | — | 18.4% | ||
| Q3 25 | 35.1% | — | ||
| Q2 25 | 33.8% | -7.5% | ||
| Q1 25 | 37.1% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | 29.9% | 13.8% | ||
| Q2 24 | 34.0% | 15.0% | ||
| Q1 24 | -1.7% | 22.1% |
| Q4 25 | — | 12.8% | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 7.5% | -5.6% | ||
| Q1 25 | 7.0% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | -48.9% | 11.6% | ||
| Q2 24 | -28.5% | 13.3% | ||
| Q1 24 | -372.8% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | $0.44 | — | ||
| Q2 25 | $0.10 | $-0.11 | ||
| Q1 25 | $0.10 | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $-0.61 | $0.21 | ||
| Q2 24 | $-0.36 | $0.26 | ||
| Q1 24 | $-4.67 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $825.7M | $172.9M |
| Total DebtLower is stronger | $3.1B | $260.0M |
| Stockholders' EquityBook value | $-89.8M | $2.0B |
| Total Assets | $4.5B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $825.7M | $172.9M | ||
| Q3 25 | $647.6M | — | ||
| Q2 25 | $531.8M | $162.2M | ||
| Q1 25 | $629.0M | $140.7M | ||
| Q4 24 | $578.0M | $177.5M | ||
| Q3 24 | $397.5M | $187.5M | ||
| Q2 24 | $445.7M | $152.9M | ||
| Q1 24 | $333.2M | $145.3M |
| Q4 25 | $3.1B | $260.0M | ||
| Q3 25 | $3.3B | — | ||
| Q2 25 | $3.2B | $346.0M | ||
| Q1 25 | $3.4B | $330.0M | ||
| Q4 24 | $3.3B | $300.0M | ||
| Q3 24 | $3.5B | $300.0M | ||
| Q2 24 | $3.6B | $319.0M | ||
| Q1 24 | $3.5B | $389.0M |
| Q4 25 | $-89.8M | $2.0B | ||
| Q3 25 | $38.1M | — | ||
| Q2 25 | $-98.4M | $1.9B | ||
| Q1 25 | $-184.4M | $2.0B | ||
| Q4 24 | $-314.4M | $2.1B | ||
| Q3 24 | $-284.7M | $2.1B | ||
| Q2 24 | $-308.3M | $2.1B | ||
| Q1 24 | $-163.2M | $2.0B |
| Q4 25 | $4.5B | $2.5B | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $4.5B | $2.6B | ||
| Q1 25 | $4.4B | $2.6B | ||
| Q4 24 | $4.2B | $2.7B | ||
| Q3 24 | $4.6B | $2.7B | ||
| Q2 24 | $4.5B | $2.7B | ||
| Q1 24 | $4.6B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | 85.85× | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $246.9M | — |
| Free Cash FlowOCF − Capex | $178.6M | — |
| FCF MarginFCF / Revenue | 70.3% | — |
| Capex IntensityCapex / Revenue | 26.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $718.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $246.9M | — | ||
| Q3 25 | $251.3M | — | ||
| Q2 25 | $237.7M | $98.2M | ||
| Q1 25 | $200.3M | $41.1M | ||
| Q4 24 | $344.4M | $84.3M | ||
| Q3 24 | $174.5M | $63.9M | ||
| Q2 24 | $134.7M | $75.5M | ||
| Q1 24 | $75.8M | $81.0M |
| Q4 25 | $178.6M | — | ||
| Q3 25 | $189.2M | — | ||
| Q2 25 | $197.7M | $93.3M | ||
| Q1 25 | $153.2M | $31.0M | ||
| Q4 24 | $282.9M | $77.5M | ||
| Q3 24 | $122.3M | $54.7M | ||
| Q2 24 | $74.2M | $57.5M | ||
| Q1 24 | $14.8M | $64.5M |
| Q4 25 | 70.3% | — | ||
| Q3 25 | 41.6% | — | ||
| Q2 25 | 45.6% | 29.4% | ||
| Q1 25 | 34.8% | 9.8% | ||
| Q4 24 | 111.5% | 26.1% | ||
| Q3 24 | 29.1% | 18.9% | ||
| Q2 24 | 17.0% | 18.8% | ||
| Q1 24 | 3.5% | 21.3% |
| Q4 25 | 26.9% | — | ||
| Q3 25 | 13.6% | — | ||
| Q2 25 | 9.2% | 1.5% | ||
| Q1 25 | 10.7% | 3.2% | ||
| Q4 24 | 24.2% | 2.3% | ||
| Q3 24 | 12.4% | 3.2% | ||
| Q2 24 | 13.9% | 5.9% | ||
| Q1 24 | 14.6% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 7.36× | — | ||
| Q1 25 | 6.52× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IHS
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
